Autres langues AIM ImmunoTech Inc.

Actions

AIM

US00901B1052

Marché Fermé - Nyse Autres places de cotation 22:10:00 12/06/2024			Varia. 5j.	Varia. 1 janv.
0,3828 ^USD	+1,36 %		+1,81 %	-12,98 %

16/05	Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024
15/05	AIM ImmunoTech Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference	10/06
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series	03/06
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering	31/05
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences	20/05
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update	16/05
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	09/05
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	06/05
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	29/04
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	29/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	18/04
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	15/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	11/04
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
Challenges To Advance Notice Bylaws Are Spiking	08/04
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	02/04
North American Morning Briefing : Stocks Seen -2-	02/04
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues AIM ImmunoTech Inc.

Actions

AIM

US00901B1052

Autres langues

Filtres